Optimizing the Use of Renin‐Angiotensin System Inhibition in Advanced Chronic Kidney Disease
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · 30.11.2024
DOI: 10.71749/pkj.58 ↗Kurz gefasst
Fachartikel in der Zeitschrift Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT), erschienen am 30.11.2024. Verfasst von Ferreira und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Chronic kidney disease (CKD) affects millions of people worldwide and is a major public health problem. Renin‐angiotensin system inhibitors are the backbone drugs for preventing CKD progression but have potential side effects, such as hyperkalemia or acute decrease in glomerular filtration rate, which can prevent physicians from starting the drugs, or even lead physicians to stop the drug when already in use in advanced CKD patients. In this review, the princi‐ pal studies performed on this topic are summarized.
Schlagwörter
Zitieren
APA
Ferreira, & Carina, A. (2024). Optimizing the Use of Renin‐Angiotensin System Inhibition in Advanced Chronic Kidney Disease. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). https://doi.org/10.71749/pkj.58
Vancouver
Ferreira, Carina A. Optimizing the Use of Renin‐Angiotensin System Inhibition in Advanced Chronic Kidney Disease. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). 2024. doi:10.71749/pkj.58
BibTeX
@article{Ferreira2024,
author = {Ferreira and Carina, Ana},
title = {Optimizing the Use of Renin‐Angiotensin System Inhibition in Advanced Chronic Kidney Disease},
journal = {Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)},
year = {2024},
doi = {10.71749/pkj.58}
}
EUVIMED